A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.
Liu K, Zheng X, Lu D, Tan Y, Hou C, Dai J, Shi W, Jiang B, Yao Y, Lu Y, Cao Q, Chen R, Zhang W, Xie J, Chen L, Jiang M, Zhang Z, Liu L, Liu J, Li J, Lv W, Wu X.
Liu K, et al. Among authors: hou c.
Radiol Med. 2024 Jan;129(1):14-28. doi: 10.1007/s11547-023-01736-0. Epub 2023 Oct 20.
Radiol Med. 2024.
PMID: 37863847